ClinicalTrials.gg
Not yet recruitingNCT07071571IONMUpdated Jul 17, 2025

New Intraoperative Nerve Monitoring Device

An interventional study of neuromonitoring in Thryoid Cancer and parathyrıoid Adenoma, sponsored by SB Istanbul Education and Research Hospital. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by SB Istanbul Education and Research Hospital · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study is testing a new device developed to protect the recurrent laryngeal nerve, which is at risk of damage during thyroid and parathyroid surgeries.

Read the detailed description

This study is testing a new device developed to protect the recurrent laryngeal nerve, which is at risk of damage during thyroid and parathyroid surgeries. Such devices are still used in surgical routine, but research has been initiated on this subject due to the higher sensitivity and reliability of this new device.

02

Conditions studied

  • Thryoid Cancer
  • parathyrıoid Adenoma

Keywords

  • neuromonitorization
  • introperative
  • recurrent nerve
  • new device
03

In context

Lead sponsor

SB Istanbul Education and Research Hospital is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-70, diagnosis of benign/malignant thyroid disease,

Exclusion criteria

Exclusion Criteria:

  • History of previous nerve injury, concomitant neurological disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    thyro,d cases

    Device: neuromonitoring

Interventions

  • Deviceneuromonitoring

    new neuromonitorin device will use

06

What researchers measure

Primary outcomes

  1. recurrent nerve identification

    nerve will be identified with new device

    Time frame: introperatively

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — No need

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Jan 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2025
First posted
Jul 17, 2025
StartEst.
Aug 1, 2025
Primary completionEst.
Jan 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07071571
Lead sponsor
SB Istanbul Education and Research Hospital
Responsible party
Erhan Aysan (Prof Dr, SB Istanbul Education and Research Hospital) — Principal investigator
First posted
Jul 17, 2025
Start date
Aug 1, 2025 (estimated)
Primary completion
Jan 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jul 17, 2025

Study contacts

erhan aysan, MD Prof
Contact
erhanaysan@hotmail.com
+902165785000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion